论文部分内容阅读
目的探讨头颈部肿瘤患者特异性细胞免疫反应水平,为头颈部肿瘤细胞免疫治疗提供实验依据。方法选择2013年3月-2014年7月新疆医科大学附属肿瘤医院病理明确诊断的头颈部肿瘤初治患者55例(头颈部肿瘤组)和同期健康体检者100例(健康对照组),用酶联免疫斑点法(ELISpot法)检测研究对象外周血T细胞对HPV全基因组序列表达的E1、E2、E4、E5、E6、E7、L1及L2全部蛋白抗原肽池的特异性细胞免疫反应水平。结果头颈部肿瘤组在E1-L2各肽池中CTL免疫阳性反应频率明显高于健康对照组,其差异均有统计学意义(P<0.05);头颈肿瘤组T细胞对HPV抗原肽E6、E7肽池特异性CTL免疫在反应强度上都显著高于健康对照组,差异有统计学意义(P<0.05)。结论 HPV抗原E6、E7蛋白可能为导致头颈部肿瘤发生、发展的致瘤蛋白及头颈部肿瘤免疫治疗的潜在优先靶点。
Objective To investigate the level of specific cellular immune responses in head and neck cancer patients and provide experimental evidence for immunotherapy of head and neck cancer cells. Methods From March 2013 to July 2014, 55 patients (head and neck cancer group) and 100 healthy subjects (control group) with initial diagnosis of head and neck cancer diagnosed at the Affiliated Tumor Hospital of Xinjiang Medical University, ELISpot assay was used to detect the specific cellular immune responses of peripheral blood T cells in all the peptide antigen pools of E1, E2, E4, E5, E6, E7, L1 and L2 expressed by HPV genome sequence Level. Results The frequency of CTL immunoreactivity in each peptide pool of head and neck cancer group was significantly higher than that of healthy control group (P <0.05). T cells in head and neck tumor group had higher expression of HPV antigen peptides E6, E7 peptide pool specific CTL immunoreactivity were significantly higher than the healthy control group, the difference was statistically significant (P <0.05). Conclusion The HPV antigen E6 and E7 proteins may be potential tumor targets for the tumorigenesis and development of head and neck tumors and tumor immunotherapy of head and neck.